• Publications
  • Influence
A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2.
Findings define a novel signaling pathway in platelets whereby activation of CLEC-2 by rhodocytin leads to tyrosine phosphorylation of its cytosolic tail, binding of Syk and initiation of downstream tyrosination events, and activation of PLCgamma2.
Involvement of the Snake Toxin Receptor CLEC-2, in Podoplanin-mediated Platelet Activation, by Cancer Cells*♦
It is suggested that CLEC-2 is a physiological target protein of podoplanin and imply that it is involved in podoplanIn-induced platelet aggregation, tumor metastasis, and other cellular responses related to podoplan in.
Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum.
The release of Sph-1-P from activated platelets may be involved in a variety of physiological and pathophysiological processes, including thrombosis, hemostasis, atherosclerosis and wound healing.
Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells.
Sph-1-P, rather than LPA, is a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells, under the conditions in which critical platelet-endothelial interactions occur.
Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer.
An as-yet-undefined but important role played by RANTES in carcinogenesis is suggested, as well as the possibility that a RantES assay in tissue surrounding a tumor or postoperative tumor site may help predict prognosis in patients with progressive breast or cervical cancer.
Sphingosine 1-phosphate: synthesis and release.
Essential in Vivo Roles of the C-type Lectin Receptor CLEC-2
It is proposed that CLEC-2 could be an ideal novel target protein for an anti-platelet drug, which inhibits pathological thrombus formation but not physiological hemostasis.